Galvan-Turner Valerie B, Chang Jenny, Ziogas Argyrios, Bristow Robert E
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, Orange, CA, United States.
Department of Epidemiology, University of California Irvine, Irvine, CA, United States.
Gynecol Oncol. 2015 Dec;139(3):495-9. doi: 10.1016/j.ygyno.2015.09.015. Epub 2015 Sep 24.
To develop an observed-to-expected ratio (O/E) for adherence to National Comprehensive Cancer Network (NCCN) ovarian cancer treatment guidelines as a risk-adjusted hospital measure of quality care correlated with disease-specific survival.
Consecutive patients with stages I-IV epithelial ovarian cancer were identified from the California Cancer Registry (1/1/96-12/31/06). Using a fit logistic regression model, O/E for guideline adherence was calculated for each hospital and distributed into quartiles stratified by hospital annual case volume: lowest O/E quartile or annual hospital case volume <5, middle two O/E quartiles and volume ≥5, and highest O/E quartile and volume ≥5. A multivariable logistic regression model was used to characterize the independent effect of hospital O/E on ovarian cancer-specific survival.
Overall, 18,491 patients were treated at 405 hospitals; 37.3% received guideline adherent care. Lowest O/E hospitals (n=285) treated 4661 patients (25.2%), mean O/E=0.77±0.55 and median survival 38.9months (95%CI=36.2-42.0months). Intermediate O/E hospitals (n=85) treated 8715 patients (47.1%), mean O/E=0.87±0.17 and median survival of 50.5months (95% CI=48.4-52.8months). Highest O/E hospitals (n=35) treated 5115 patients (27.7%), mean O/E=1.34±0.14 and median survival of 53.8months (95% CI=50.2-58.2months). After controlling for other variables, treatment at highest O/E hospitals was associated with independent and statistically significant improvement in ovarian cancer-specific survival compared to intermediate O/E (HR=1.06, 95% CI=1.01-1.11) and lowest O/E (1.16, 95% CI=1.10-1.23) hospitals.
Calculation of hospital-specific O/E for NCCN treatment guideline adherence, combined with minimum case volume criterion, as a measure of ovarian cancer quality of care is feasible and is an independent predictor of survival.
制定国家综合癌症网络(NCCN)卵巢癌治疗指南依从性的观察与预期比值(O/E),作为与疾病特异性生存相关的风险调整后的医院医疗质量衡量指标。
从加利福尼亚癌症登记处(1996年1月1日至2006年12月31日)识别出连续的I-IV期上皮性卵巢癌患者。使用拟合逻辑回归模型,计算每家医院指南依从性的O/E,并按医院年度病例量分层分为四分位数:最低O/E四分位数或医院年度病例量<5,中间两个O/E四分位数且病例量≥5,以及最高O/E四分位数且病例量≥5。使用多变量逻辑回归模型来描述医院O/E对卵巢癌特异性生存的独立影响。
总体而言,405家医院共治疗了18491例患者;37.3%接受了符合指南的治疗。最低O/E医院(n = 285)治疗了4661例患者(25.2%),平均O/E = 0.77±0.55,中位生存期为38.9个月(95%CI = 36.2 - 42.0个月)。中等O/E医院(n = 85)治疗了8715例患者(47.1%),平均O/E = 0.87±0.17,中位生存期为50.5个月(95%CI = 48.4 - 52.8个月)。最高O/E医院(n = 35)治疗了5115例患者(27.7%),平均O/E = 1.34±0.14,中位生存期为53.8个月(95%CI = 50.2 - 58.2个月)。在控制其他变量后,与中等O/E医院(HR = 1.06,95%CI = 1.01 - 1.11)和最低O/E医院(1.16,95%CI = 1.10 - 1.23)相比,在最高O/E医院接受治疗与卵巢癌特异性生存的独立且具有统计学意义的改善相关。
计算针对NCCN治疗指南依从性的医院特异性O/E,并结合最低病例量标准,作为卵巢癌医疗质量的衡量指标是可行的,并且是生存的独立预测因素。